Just a few neoantigens may be enough for T cells to control prostate cancer

In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.

What's Next in CAR T Cell Therapy?

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Targeting neoantigens to augment antitumour immunity

Developing neoantigen-targeted T cell–based treatments for solid

Nanomaterials in tumor immunotherapy: new strategies and

IJMS, Free Full-Text

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments, Journal of Translational Medicine

Engineering neoantigen vaccines to improve cancer personalized

Frontiers Neoantigens and NK Cells: “Trick or Treat” the Cancers?

Informatics for Cancer Immunotherapy